Therapeutic  ||| S:0 E:12 ||| JJ
effects  ||| S:12 E:20 ||| NNS
of  ||| S:20 E:23 ||| IN
bone  ||| S:23 E:28 ||| JJ
marrow-derived  ||| S:28 E:43 ||| JJ
mesenchymal  ||| S:43 E:55 ||| NNS
stem  ||| S:55 E:60 ||| VBP
cells  ||| S:60 E:66 ||| NNS
on  ||| S:66 E:69 ||| IN
radiation-induced  ||| S:69 E:87 ||| JJ
lung  ||| S:87 E:92 ||| NN
injury  ||| S:92 E:99 ||| NN
Radiation-induced  ||| S:99 E:117 ||| JJ
lung  ||| S:117 E:122 ||| NN
injury  ||| S:122 E:129 ||| NN
( ||| S:129 E:130 ||| -LRB-
RILI ||| S:130 E:134 ||| NNP
)  ||| S:134 E:136 ||| -RRB-
is  ||| S:136 E:139 ||| VBZ
a  ||| S:139 E:141 ||| DT
fatal  ||| S:141 E:147 ||| JJ
condition  ||| S:147 E:157 ||| NN
featured  ||| S:157 E:166 ||| VBN
by  ||| S:166 E:169 ||| IN
interstitial  ||| S:169 E:182 ||| JJ
pneumonitis  ||| S:182 E:194 ||| NN
and  ||| S:194 E:198 ||| CC
fibrosis ||| S:198 E:206 ||| NN
.  ||| S:206 E:208 ||| .
Mesenchymal  ||| S:208 E:220 ||| JJ
stem  ||| S:220 E:225 ||| NN
cells  ||| S:225 E:231 ||| NNS
( ||| S:231 E:232 ||| -LRB-
MSCs ||| S:232 E:236 ||| NNP
)  ||| S:236 E:238 ||| -RRB-
have  ||| S:238 E:243 ||| VBP
been  ||| S:243 E:248 ||| VBN
widely  ||| S:248 E:255 ||| RB
used  ||| S:255 E:260 ||| VBN
for  ||| S:260 E:264 ||| IN
treating  ||| S:264 E:273 ||| VBG
RILI  ||| S:273 E:278 ||| NNP
in  ||| S:278 E:281 ||| IN
rodent  ||| S:281 E:288 ||| JJ
models ||| S:288 E:294 ||| NNS
.  ||| S:294 E:296 ||| .
In  ||| S:296 E:299 ||| IN
the  ||| S:299 E:303 ||| DT
present  ||| S:303 E:311 ||| JJ
study ||| S:311 E:316 ||| NN
,  ||| S:316 E:318 ||| ,
we  ||| S:318 E:321 ||| PRP
aimed  ||| S:321 E:327 ||| VBD
to  ||| S:327 E:330 ||| TO
investigate  ||| S:330 E:342 ||| VB
whether  ||| S:342 E:350 ||| IN
the  ||| S:350 E:354 ||| DT
therapeutic  ||| S:354 E:366 ||| JJ
effects  ||| S:366 E:374 ||| NNS
of  ||| S:374 E:377 ||| IN
human  ||| S:377 E:383 ||| JJ
bone  ||| S:383 E:388 ||| NN
marrow-derived  ||| S:388 E:403 ||| JJ
mesenchymal  ||| S:403 E:415 ||| NNS
stem  ||| S:415 E:420 ||| VBP
cells  ||| S:420 E:426 ||| NNS
( ||| S:426 E:427 ||| -LRB-
hBM-MSCs ||| S:427 E:435 ||| NNP
)  ||| S:435 E:437 ||| -RRB-
on  ||| S:437 E:440 ||| IN
RILI  ||| S:440 E:445 ||| NNP
were  ||| S:445 E:450 ||| VBD
in  ||| S:450 E:453 ||| IN
a  ||| S:453 E:455 ||| DT
dose-dependent  ||| S:455 E:470 ||| JJ
manner ||| S:470 E:476 ||| NN
.  ||| S:476 E:478 ||| .
A  ||| S:478 E:480 ||| DT
total  ||| S:480 E:486 ||| NN
of  ||| S:486 E:489 ||| IN
100 mice  ||| S:489 E:498 ||| NNP
were  ||| S:498 E:503 ||| VBD
randomly  ||| S:503 E:512 ||| RB
divided  ||| S:512 E:520 ||| VBN
into ||| S:520 E:524 ||| IN
:  ||| S:524 E:526 ||| :
a  ||| S:526 E:528 ||| DT
control  ||| S:528 E:536 ||| NN
group  ||| S:536 E:542 ||| NN
( ||| S:542 E:543 ||| -LRB-
n=25 ||| S:543 E:547 ||| NNP
) ||| S:547 E:548 ||| -RRB-
,  ||| S:548 E:550 ||| ,
subject  ||| S:550 E:558 ||| JJ
to  ||| S:558 E:561 ||| TO
lung  ||| S:561 E:566 ||| NN
irradiation  ||| S:566 E:578 ||| NN
and  ||| S:578 E:582 ||| CC
injection  ||| S:582 E:592 ||| NN
of  ||| S:592 E:595 ||| IN
phosphate-buffered  ||| S:595 E:614 ||| JJ
solution  ||| S:614 E:623 ||| NN
( ||| S:623 E:624 ||| -LRB-
PBS ||| S:624 E:627 ||| NNP
)  ||| S:627 E:629 ||| -RRB-
via  ||| S:629 E:633 ||| IN
the  ||| S:633 E:637 ||| DT
tail  ||| S:637 E:642 ||| JJ
vein ||| S:642 E:646 ||| NN
;  ||| S:646 E:648 ||| :
and  ||| S:648 E:652 ||| CC
the  ||| S:652 E:656 ||| DT
hBM-MSC  ||| S:656 E:664 ||| JJ
group ||| S:664 E:669 ||| NN
,  ||| S:669 E:671 ||| ,
subject  ||| S:671 E:679 ||| JJ
to  ||| S:679 E:682 ||| TO
lung  ||| S:682 E:687 ||| NN
irradiation  ||| S:687 E:699 ||| VBZ
followed  ||| S:699 E:708 ||| VBN
by  ||| S:708 E:711 ||| IN
injection  ||| S:711 E:721 ||| NN
of  ||| S:721 E:724 ||| IN
a  ||| S:724 E:726 ||| DT
low  ||| S:726 E:730 ||| JJ
dose  ||| S:730 E:735 ||| NN
( ||| S:735 E:736 ||| -LRB-
1x103 hBM-MSCs ||| S:736 E:750 ||| FW
/ ||| S:750 E:751 ||| FW
g ||| S:751 E:752 ||| FW
) ||| S:752 E:753 ||| -RRB-
,  ||| S:753 E:755 ||| ,
medium  ||| S:755 E:762 ||| JJ
dose  ||| S:762 E:767 ||| NN
( ||| S:767 E:768 ||| -LRB-
5x103 hBM-MSCs ||| S:768 E:782 ||| FW
/ ||| S:782 E:783 ||| FW
g ||| S:783 E:784 ||| FW
)  ||| S:784 E:786 ||| -RRB-
and  ||| S:786 E:790 ||| CC
high  ||| S:790 E:795 ||| JJ
dose  ||| S:795 E:800 ||| NN
( ||| S:800 E:801 ||| -LRB-
1x104 hBM-MSCs ||| S:801 E:815 ||| FW
/ ||| S:815 E:816 ||| FW
g ||| S:816 E:817 ||| FW
)  ||| S:817 E:819 ||| -RRB-
of  ||| S:819 E:822 ||| IN
hBM-MSCs  ||| S:822 E:831 ||| JJ
in  ||| S:831 E:834 ||| IN
PBS  ||| S:834 E:838 ||| NNP
through  ||| S:838 E:846 ||| IN
the  ||| S:846 E:850 ||| DT
tail  ||| S:850 E:855 ||| JJ
vein ||| S:855 E:859 ||| NN
,  ||| S:859 E:861 ||| ,
respectively ||| S:861 E:873 ||| RB
.  ||| S:873 E:875 ||| .
After  ||| S:875 E:881 ||| IN
sacrifice ||| S:881 E:890 ||| NN
,  ||| S:890 E:892 ||| ,
the  ||| S:892 E:896 ||| DT
pulmonary  ||| S:896 E:906 ||| JJ
tissues  ||| S:906 E:914 ||| NNS
were  ||| S:914 E:919 ||| VBD
subject  ||| S:919 E:927 ||| JJ
to  ||| S:927 E:930 ||| TO
hematoxylin  ||| S:930 E:942 ||| VB
and eosin  ||| S:942 E:952 ||| NNP
( ||| S:952 E:953 ||| -LRB-
H ||| S:953 E:954 ||| NNP
& ||| S:954 E:955 ||| CC
E ||| S:955 E:956 ||| NNP
)  ||| S:956 E:958 ||| -RRB-
staining ||| S:958 E:966 ||| NN
,  ||| S:966 E:968 ||| ,
Masson ||| S:968 E:974 ||| NNP
's  ||| S:974 E:977 ||| POS
trichrome  ||| S:977 E:987 ||| JJ
staining  ||| S:987 E:996 ||| NN
and  ||| S:996 E:1000 ||| CC
immunohistochemical  ||| S:1000 E:1020 ||| JJ
staining  ||| S:1020 E:1029 ||| NN
to  ||| S:1029 E:1032 ||| TO
investigate  ||| S:1032 E:1044 ||| VB
the  ||| S:1044 E:1048 ||| DT
pathological  ||| S:1048 E:1061 ||| JJ
changes ||| S:1061 E:1068 ||| NNS
.  ||| S:1068 E:1070 ||| .
Immunofluorescent  ||| S:1070 E:1088 ||| JJ
staining  ||| S:1088 E:1097 ||| NN
was  ||| S:1097 E:1101 ||| VBD
performed  ||| S:1101 E:1111 ||| VBN
to  ||| S:1111 E:1114 ||| TO
evaluate  ||| S:1114 E:1123 ||| VB
the  ||| S:1123 E:1127 ||| DT
differentiation  ||| S:1127 E:1143 ||| JJ
capacity  ||| S:1143 E:1152 ||| NN
of  ||| S:1152 E:1155 ||| IN
hBM-MSCs  ||| S:1155 E:1164 ||| JJ
in vivo  ||| S:1164 E:1172 ||| NN
by  ||| S:1172 E:1175 ||| IN
analyzing  ||| S:1175 E:1185 ||| VBG
the  ||| S:1185 E:1189 ||| DT
expression  ||| S:1189 E:1200 ||| NN
of  ||| S:1200 E:1203 ||| IN
SPC  ||| S:1203 E:1207 ||| NNP
and  ||| S:1207 E:1211 ||| CC
PECAM.  ||| S:1211 E:1218 ||| NNP
hBM-MSCs  ||| S:1218 E:1227 ||| NNP
improved  ||| S:1227 E:1236 ||| VBD
the  ||| S:1236 E:1240 ||| DT
survival  ||| S:1240 E:1249 ||| NN
rate  ||| S:1249 E:1254 ||| NN
and  ||| S:1254 E:1258 ||| CC
histopathological  ||| S:1258 E:1276 ||| JJ
features  ||| S:1276 E:1285 ||| NNS
in  ||| S:1285 E:1288 ||| IN
the  ||| S:1288 E:1292 ||| DT
irradiated  ||| S:1292 E:1303 ||| JJ
mice ||| S:1303 E:1307 ||| NNS
,  ||| S:1307 E:1309 ||| ,
especially  ||| S:1309 E:1320 ||| RB
in  ||| S:1320 E:1323 ||| IN
the  ||| S:1323 E:1327 ||| DT
low-dose  ||| S:1327 E:1336 ||| JJ
group ||| S:1336 E:1341 ||| NN
.  ||| S:1341 E:1343 ||| .
Marked  ||| S:1343 E:1350 ||| JJ
decrease  ||| S:1350 E:1359 ||| NN
in  ||| S:1359 E:1362 ||| IN
collagen  ||| S:1362 E:1371 ||| JJ
deposition  ||| S:1371 E:1382 ||| NN
was  ||| S:1382 E:1386 ||| VBD
noted  ||| S:1386 E:1392 ||| VBN
in  ||| S:1392 E:1395 ||| IN
the  ||| S:1395 E:1399 ||| DT
irradiated  ||| S:1399 E:1410 ||| JJ
mice  ||| S:1410 E:1415 ||| NNS
treated  ||| S:1415 E:1423 ||| VBN
using  ||| S:1423 E:1429 ||| VBG
a  ||| S:1429 E:1431 ||| DT
low  ||| S:1431 E:1435 ||| JJ
dose  ||| S:1435 E:1440 ||| NN
of  ||| S:1440 E:1443 ||| IN
hBM-MSCs ||| S:1443 E:1451 ||| JJ
.  ||| S:1451 E:1453 ||| .
In  ||| S:1453 E:1456 ||| IN
addition ||| S:1456 E:1464 ||| NN
,  ||| S:1464 E:1466 ||| ,
hBM-MSCs  ||| S:1466 E:1475 ||| JJ
attenuated  ||| S:1475 E:1486 ||| JJ
secretion  ||| S:1486 E:1496 ||| NN
and  ||| S:1496 E:1500 ||| CC
expression  ||| S:1500 E:1511 ||| NN
of  ||| S:1511 E:1514 ||| IN
IL-10  ||| S:1514 E:1520 ||| NNP
and  ||| S:1520 E:1524 ||| CC
increased  ||| S:1524 E:1534 ||| VBD
the  ||| S:1534 E:1538 ||| DT
expression  ||| S:1538 E:1549 ||| NN
of  ||| S:1549 E:1552 ||| IN
TNF-α ||| S:1552 E:1557 ||| JJ
.  ||| S:1557 E:1559 ||| .
Furthermore ||| S:1559 E:1570 ||| RB
,  ||| S:1570 E:1572 ||| ,
hBM-MSCs  ||| S:1572 E:1581 ||| NNP
had  ||| S:1581 E:1585 ||| VBD
the  ||| S:1585 E:1589 ||| DT
potential  ||| S:1589 E:1599 ||| JJ
to  ||| S:1599 E:1602 ||| TO
differentiate  ||| S:1602 E:1616 ||| VB
into  ||| S:1616 E:1621 ||| IN
functional  ||| S:1621 E:1632 ||| JJ
cells  ||| S:1632 E:1638 ||| NNS
upon  ||| S:1638 E:1643 ||| IN
lung  ||| S:1643 E:1648 ||| NN
injury ||| S:1648 E:1654 ||| NN
.  ||| S:1654 E:1656 ||| .
Low-dose  ||| S:1656 E:1665 ||| NNP
hBM-MSCs  ||| S:1665 E:1674 ||| NNP
contributed  ||| S:1674 E:1686 ||| VBD
to  ||| S:1686 E:1689 ||| TO
functional  ||| S:1689 E:1700 ||| VB
recovery  ||| S:1700 E:1709 ||| NN
in  ||| S:1709 E:1712 ||| IN
mice  ||| S:1712 E:1717 ||| NNS
with  ||| S:1717 E:1722 ||| IN
RILI ||| S:1722 E:1726 ||| NNP
.  ||| S:1726 E:1728 ||| .
